a Internal Medicine Department , Hospital Universitari Vall d'Hebron , Barcelona , Spain.
b Nuclear Medicine Department , Hospital Universitari Vall d'Hebron , Barcelona , Spain.
Amyloid. 2018 Jun;25(2):109-114. doi: 10.1080/13506129.2018.1467313. Epub 2018 Apr 28.
Amyloidosis comprises a group of heterogeneous conditions. To ascertain the burden of disease is important because it can determine the treatment as well as the evolution of the disease. Recent reports have shown good results in diagnosing cardiac amyloidosis using F-florbetapir. We hypothesize that combining whole body PET/CT with F-Florbetapir can be useful to characterize the burden of the disease. We included 25 patients, 13 of them with different types of amyloidosis, and 12 with Alzheimer's disease as controls. Target-to-background ratio was computed for multiple organ using maximum standardized uptake values. Organ involvement was described (standardized techniques versus PET) according to different kinds of amyloidosis showing promising results in AA and AL types. Heart involvement showed poorer results when compared to tongue, lung or thyroid gland. Multiple organ involvement in patients previously labelled as having negative organ affectation could be identified. This is the first study to evaluate the utility of F-florbetapir in the assessment of the global extension of disease. Our results show that this technique is useful for its diagnosis.
淀粉样变包括一组异质性疾病。确定疾病负担很重要,因为它可以决定治疗方法以及疾病的发展。最近的报告显示,使用 F-氟脱氧葡萄糖(F-Florbetapir)诊断心脏淀粉样变性的效果良好。我们假设全身 PET/CT 结合 F-Florbetapir 可以有助于描述疾病负担。我们纳入了 25 名患者,其中 13 名患有不同类型的淀粉样变性,12 名患有阿尔茨海默病作为对照组。使用最大标准化摄取值计算了多个器官的靶标与背景比。根据不同类型的淀粉样变性描述了器官受累情况(标准技术与 PET),AA 和 AL 型显示出有希望的结果。与舌、肺或甲状腺相比,心脏受累的结果较差。在以前被标记为器官受累阴性的患者中,可以识别出多个器官受累。这是第一项评估 F-氟脱氧葡萄糖在评估疾病整体范围中的效用的研究。我们的结果表明,该技术对于其诊断是有用的。